NZ723971A - Methods and compositions for treating ewings sarcoma family of tumors - Google Patents
Methods and compositions for treating ewings sarcoma family of tumorsInfo
- Publication number
- NZ723971A NZ723971A NZ723971A NZ72397113A NZ723971A NZ 723971 A NZ723971 A NZ 723971A NZ 723971 A NZ723971 A NZ 723971A NZ 72397113 A NZ72397113 A NZ 72397113A NZ 723971 A NZ723971 A NZ 723971A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compositions
- methods
- treating
- tumors
- sarcoma family
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000006168 Ewing Sarcoma Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 210000005170 neoplastic cell Anatomy 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261623349P | 2012-04-12 | 2012-04-12 | |
| NZ700612A NZ700612A (en) | 2012-04-12 | 2013-04-11 | Methods and compositions for treating ewings sarcoma family of tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ723971A true NZ723971A (en) | 2018-01-26 |
Family
ID=49328171
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ723971A NZ723971A (en) | 2012-04-12 | 2013-04-11 | Methods and compositions for treating ewings sarcoma family of tumors |
| NZ700612A NZ700612A (en) | 2012-04-12 | 2013-04-11 | Methods and compositions for treating ewings sarcoma family of tumors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ700612A NZ700612A (en) | 2012-04-12 | 2013-04-11 | Methods and compositions for treating ewings sarcoma family of tumors |
Country Status (13)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8232310B2 (en) | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| NZ723971A (en) * | 2012-04-12 | 2018-01-26 | Univ Georgetown | Methods and compositions for treating ewings sarcoma family of tumors |
| KR20160065986A (ko) | 2013-10-24 | 2016-06-09 | 조지타운 유니버시티 | 암 치료용 방법 및 조성물 |
| CN111777596A (zh) | 2014-10-09 | 2020-10-16 | 英克特诺治疗公司 | 吲哚酮化合物及其用途 |
| CN107530283A (zh) | 2015-03-03 | 2018-01-02 | 奎尔波特股份有限公司 | 组合脂质体药物制剂 |
| CA2977397A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
| CN109219594B (zh) * | 2016-03-31 | 2022-10-11 | 英克特诺治疗公司 | 吲哚啉类似物及其用途 |
| CA3029851A1 (en) | 2016-07-29 | 2018-02-01 | Oncternal Therapeutics, Inc. | Uses of indoline compounds such as tk216 for the treatment of cancer |
| WO2018119069A1 (en) * | 2016-12-21 | 2018-06-28 | Mooberry Susan L | Altertoxin ii as a selective inhibitor of ewing family of tumor cells |
| CN108186630B (zh) * | 2017-12-18 | 2020-07-31 | 温州医科大学 | 靛红类似物在制备抗肿瘤药物中的应用 |
| CN110870917B (zh) * | 2018-09-03 | 2022-03-15 | 上海市第一人民医院 | Ews或其上调剂在制备治疗糖尿病及防治糖尿病个体肿瘤发生的药物中的应用 |
| US20230000823A1 (en) * | 2021-06-09 | 2023-01-05 | University Of Rochester | Compounds and Methods for the Treatment of Acute Myelogenous Leukemia |
| CN114057626B (zh) * | 2021-12-07 | 2023-06-30 | 山东第一医科大学(山东省医学科学院) | 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物 |
| WO2023178040A2 (en) * | 2022-03-13 | 2023-09-21 | University Of Virginia Patent Foundation | Inhibitors of ews-fli1 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1288436C (en) | 1983-07-22 | 1991-09-03 | David Paul Hesson | Phenylquinolinecarboxylic acids and derivatives as antitumor agents |
| JP2002531498A (ja) | 1998-12-04 | 2002-09-24 | ニューロサーチ、アクティーゼルスカブ | イオンチャネル活性剤としてのイサチン誘導体の使用方法 |
| CN1155572C (zh) | 2001-01-19 | 2004-06-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 吲哚类衍生物及其抗肿瘤用途 |
| US20030157486A1 (en) | 2001-06-21 | 2003-08-21 | Graff Jonathan M. | Methods to identify signal sequences |
| JP4584987B2 (ja) | 2004-04-30 | 2010-11-24 | アルニラム ファーマスーティカルズ インコーポレイテッド | Ｃ５修飾ピリミジンを含むオリゴヌクレオチド |
| AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| WO2006117414A1 (es) | 2005-04-29 | 2006-11-09 | Proyecto De Biomedicina Cima, S.L. | Modelo animal no humano de sarcoma |
| WO2008046083A2 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
| CA2711003C (en) * | 2006-12-29 | 2017-02-21 | Georgetown University | Targeting of ews-fli1 as anti-tumor therapy |
| US8232310B2 (en) | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| EP2154966B1 (en) * | 2007-04-20 | 2013-08-21 | The Research Foundation Of State University Of New York | Benzimidazoles and pharmaceutical compositions thereof |
| US8377992B2 (en) * | 2007-10-22 | 2013-02-19 | The Wistar Institute | TRBD-binding effectors and methods for using the same to modulate telomerase activity |
| US8710068B2 (en) | 2009-01-19 | 2014-04-29 | The Trustees Of The University Of Pennsylvania | Method of treating cancer using a survivin inhibitor |
| WO2012078519A2 (en) | 2010-12-06 | 2012-06-14 | Numerate, Inc. | 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2 |
| NZ723971A (en) * | 2012-04-12 | 2018-01-26 | Univ Georgetown | Methods and compositions for treating ewings sarcoma family of tumors |
| CN103435606A (zh) | 2013-08-22 | 2013-12-11 | 中国药科大学 | CDK2与GSK3β双重抑制剂及用途 |
| KR20160065986A (ko) | 2013-10-24 | 2016-06-09 | 조지타운 유니버시티 | 암 치료용 방법 및 조성물 |
| CN111777596A (zh) | 2014-10-09 | 2020-10-16 | 英克特诺治疗公司 | 吲哚酮化合物及其用途 |
-
2013
- 2013-04-11 NZ NZ723971A patent/NZ723971A/en unknown
- 2013-04-11 MX MX2014011583A patent/MX2014011583A/es active IP Right Grant
- 2013-04-11 CA CA2869513A patent/CA2869513C/en active Active
- 2013-04-11 WO PCT/US2013/036234 patent/WO2013155341A1/en active Application Filing
- 2013-04-11 US US14/388,671 patent/US9290449B2/en active Active
- 2013-04-11 CN CN201611030609.9A patent/CN107011242B/zh active Active
- 2013-04-11 EP EP13776244.9A patent/EP2836481B1/en active Active
- 2013-04-11 KR KR1020147031650A patent/KR102145835B1/ko active IP Right Grant
- 2013-04-11 AU AU2013245812A patent/AU2013245812B2/en active Active
- 2013-04-11 JP JP2015505921A patent/JP6130491B2/ja active Active
- 2013-04-11 IN IN9228DEN2014 patent/IN2014DN09228A/en unknown
- 2013-04-11 NZ NZ700612A patent/NZ700612A/en unknown
- 2013-04-11 CN CN201380030414.2A patent/CN104395288B/zh active Active
-
2014
- 2014-10-05 IL IL234993A patent/IL234993B/en active IP Right Grant
-
2015
- 2015-08-17 HK HK15107941.8A patent/HK1207368A1/xx unknown
-
2016
- 2016-02-10 US US15/040,840 patent/US9714222B2/en active Active
-
2017
- 2017-03-06 AU AU2017201507A patent/AU2017201507B2/en active Active
- 2017-04-13 JP JP2017080017A patent/JP6345301B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160159741A1 (en) | 2016-06-09 |
| EP2836481A4 (en) | 2015-11-18 |
| EP2836481A1 (en) | 2015-02-18 |
| AU2013245812A1 (en) | 2014-11-13 |
| JP6130491B2 (ja) | 2017-05-17 |
| CN107011242B (zh) | 2020-08-07 |
| NZ700612A (en) | 2016-09-30 |
| AU2013245812B2 (en) | 2017-04-06 |
| CN107011242A (zh) | 2017-08-04 |
| EP2836481B1 (en) | 2018-12-26 |
| KR102145835B1 (ko) | 2020-08-20 |
| WO2013155341A1 (en) | 2013-10-17 |
| US20150051260A1 (en) | 2015-02-19 |
| US9714222B2 (en) | 2017-07-25 |
| AU2013245812A2 (en) | 2014-11-20 |
| MX2014011583A (es) | 2016-02-09 |
| HK1207368A1 (en) | 2016-01-29 |
| IN2014DN09228A (US20040106767A1-20040603-C00005.png) | 2015-07-10 |
| CA2869513C (en) | 2020-07-07 |
| CA2869513A1 (en) | 2013-10-17 |
| JP2015512943A (ja) | 2015-04-30 |
| AU2017201507A1 (en) | 2017-03-23 |
| JP6345301B2 (ja) | 2018-06-20 |
| CN104395288A (zh) | 2015-03-04 |
| KR20150007311A (ko) | 2015-01-20 |
| AU2017201507B2 (en) | 2018-10-04 |
| IL234993B (en) | 2019-02-28 |
| US9290449B2 (en) | 2016-03-22 |
| JP2017141290A (ja) | 2017-08-17 |
| CN104395288B (zh) | 2016-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ700612A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
| PH12017502141A1 (en) | Compounds and their methods of use | |
| EA201391626A1 (ru) | Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака | |
| PH12015501576A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| MY183661A (en) | Treatment of cancer with tor kinase inhibitors | |
| PH12016500225B1 (en) | Novel quinoline-substituted compound | |
| MX2014001218A (es) | Tratamiento de cancer de mama. | |
| MX2014002683A (es) | Derivados de benzonitrilo como inhibidores de cinasa. | |
| MD4820B1 (ro) | Compuşi dihidroizochinolinonici substituiţi | |
| UA111382C2 (uk) | Інгібітори протеїнкінази | |
| MX352975B (es) | Piridina y derivados de pirazina. | |
| NZ615270A (en) | Phosphoramidate derivatives of 5 - fluoro - 2 ‘ - deoxyuridine for use in the treatment of cancer | |
| MX2014003376A (es) | Derivados de acido benzoico como inhibidores eif4e. | |
| PH12015501088A1 (en) | Dimeric compounds | |
| GEP201706690B (en) | Novel process for making compounds for use in treatment of cancer | |
| PH12015501038A1 (en) | Inhibitors of iap | |
| MX2014008864A (es) | Derivados de triazolo[4,5-d]pirimidina. | |
| MD20160111A2 (ro) | Derivaţi diheterociclici legaţi de cicloalchil | |
| PH12015500399A1 (en) | Azaindolines | |
| AU2016204389A1 (en) | Kinase inhibitors for the treatment of cancer | |
| MX2015012600A (es) | Compuestos de tetrahidroisoquinolina-2-il-(quinazolina-4-il) metanona como inhibidores del crecimiento de células cancerígenas. | |
| NZ750581A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
| WO2013013238A3 (en) | Compounds and related compositions and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2020 BY CPA GLOBAL Effective date: 20190307 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2021 BY CPA GLOBAL Effective date: 20200306 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2022 BY CPA GLOBAL Effective date: 20210305 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2023 BY CPA GLOBAL Effective date: 20220304 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2024 BY CPA GLOBAL Effective date: 20230223 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240301 |